Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers. Results: There were 146 patients enrolled; common tumor types were colorectal, sarcoma, and ovari...

Descripción completa

Detalles Bibliográficos
Autores principales: Piha-Paul, Sarina A., Taylor, Matthew H., Spitz, Daniel, Schwartzberg, Lee, Beck, J. Thaddeus, Bauer, Todd M., Meric-Bernstam, Funda, Purkayastha, Das, Karpiak, Linda, Szpakowski, Sebastian, Braiteh, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849647/
https://www.ncbi.nlm.nih.gov/pubmed/31741715
http://dx.doi.org/10.18632/oncotarget.27251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849647/
https://www.ncbi.nlm.nih.gov/pubmed/31741715
http://dx.doi.org/10.18632/oncotarget.27251

Ejemplares similares